AR015553A1 - Composiciones de ziprasidona, y procedimiento para prepararlas - Google Patents
Composiciones de ziprasidona, y procedimiento para prepararlasInfo
- Publication number
- AR015553A1 AR015553A1 ARP990102822A ARP990102822A AR015553A1 AR 015553 A1 AR015553 A1 AR 015553A1 AR P990102822 A ARP990102822 A AR P990102822A AR P990102822 A ARP990102822 A AR P990102822A AR 015553 A1 AR015553 A1 AR 015553A1
- Authority
- AR
- Argentina
- Prior art keywords
- solution resulting
- prepare
- crystalline
- ziprasidone
- approximately
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Abstract
Composiciones que comprenden partículas de base libre de ziprasidona cristalino o de hidrocloruro de ziprasidona cristalino, que tienen un tamano medio departículas inferior a 85 micrones, y un vehículo farmacéuticamente aceptable sonsustancialment e bioequivalentes y se pueden usar paa tratar psicosis, comoesquizofrenia. Se describe tambilén el uso de dichoas partículas para preparar la composicion y un procedimiento para preparar cristales grandes dehidrocloruro de ziprasidonamonohidrato, qu e comprende las etapas de: 1) disolver base libre de ziprasidona en un disolvente que comprende THF y agua, en unarelacion volumétrica de aproximadamente 22-35 unidades de volumen de THF a aproximadamente 1,5-8 unidades de volumen deagua 2) calentar la solucion resultantede la etapa (1),3) anadir HCI a la solucion resultante de la etapa (2) y (4) enfriar la solucion resultante de la etapa (3).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8922998P | 1998-06-15 | 1998-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR015553A1 true AR015553A1 (es) | 2001-05-02 |
Family
ID=22216447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990102822A AR015553A1 (es) | 1998-06-15 | 1999-06-11 | Composiciones de ziprasidona, y procedimiento para prepararlas |
Country Status (45)
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
US7175855B1 (en) | 1999-05-27 | 2007-02-13 | Pfizer Inc. | Ziprasidone suspension |
NZ514764A (en) * | 1999-05-27 | 2004-04-30 | Pfizer Prod Inc | Ziprasidone suspension, which is taste-masked and may be used to treat psychosis |
HU230828B1 (en) | 1999-10-29 | 2018-08-28 | Euro Celtique Sa | Controlled release hydrocodone formulations |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
HU230875B1 (hu) | 2000-10-30 | 2018-11-29 | Euro-Celtique S.A. | Szabályozott hatóanyag-leadású hidrokodon készítmények |
US20040048876A1 (en) * | 2002-02-20 | 2004-03-11 | Pfizer Inc. | Ziprasidone composition and synthetic controls |
UY27668A1 (es) * | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
EP2301537A1 (en) | 2002-05-17 | 2011-03-30 | Duke University | Zonisamide for the treatment of obesity |
US7488729B2 (en) * | 2002-12-04 | 2009-02-10 | Dr. Reddy's Laboratories Limited | Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof |
WO2004050655A1 (en) * | 2002-12-04 | 2004-06-17 | Dr. Reddy's Laboratories Limited | Polymorphic forms of ziprasidone and its hydrochloride |
WO2004089948A1 (en) * | 2003-04-11 | 2004-10-21 | Hetero Drugs Limited | Novel crystalline forms of ziprasidone hydrochloride |
US7375111B2 (en) | 2003-04-29 | 2008-05-20 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
KR100880279B1 (ko) * | 2003-06-03 | 2009-01-28 | 테바 파마슈티컬 인더스트리즈 리미티드 | 결정성 지프라시돈 염산염 및 그의 제조 방법 |
US20050049295A1 (en) * | 2003-06-12 | 2005-03-03 | Dr. Reddy's Laboratories Limited | Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate |
KR20090080143A (ko) * | 2003-09-02 | 2009-07-23 | 화이자 프로덕츠 인크. | 지프라시돈의 지속 방출형 투여 형태 |
EP1628973A2 (en) * | 2003-10-24 | 2006-03-01 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
EP1687300A4 (en) * | 2003-11-28 | 2007-08-01 | Wockhardt Ltd | PROCESS FOR THE PREPARATION OF ZIPRASIDONE MONOHYDROCHLORIDE HYDRATE |
EP1592688A2 (en) * | 2003-12-18 | 2005-11-09 | Teva Pharmaceutical Industries Ltd. | Polymorphic form b2 of ziprasidone base |
US20050163858A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Ziprasidone formulations |
JP2007517901A (ja) * | 2004-01-13 | 2007-07-05 | デューク・ユニバーシティー | 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物 |
US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
ATE451367T1 (de) * | 2004-02-27 | 2009-12-15 | Ranbaxy Lab Ltd | Verfahren zur herstellung von ziprasidon |
CA2565154A1 (en) * | 2004-05-03 | 2005-11-24 | Duke University | Compositions for affecting weight loss |
WO2005107719A2 (en) * | 2004-05-06 | 2005-11-17 | Sandoz Ag | Pharmaceutical composition comprising hydrophobic drug having improved solubility |
CA2467538C (en) * | 2004-05-14 | 2010-08-24 | Apotex Pharmachem Inc. | New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same |
US20070237828A1 (en) * | 2004-06-11 | 2007-10-11 | Dr. Reddy's Laboratories Limited | Ziprasidone Dosage Form |
CA2471219A1 (en) * | 2004-06-14 | 2005-12-14 | Apotex Pharmachem Inc. | Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) |
US9044503B2 (en) * | 2004-08-27 | 2015-06-02 | University Of Kentucky Research Foundation | Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally |
BRPI0514753A (pt) * | 2004-08-31 | 2008-06-24 | Pfizer Prod Inc | formas de dosagem farmacêutica compreendendo um medicamento de baixa solubilidade e um polìmero |
EA200701065A1 (ru) * | 2004-11-16 | 2007-12-28 | Элан Фарма Интернэшнл Лтд. | Инъецируемые составы, содержащие нанодисперсный оланзапин |
US20080268034A1 (en) * | 2005-01-07 | 2008-10-30 | Girish Karanth | Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide |
US7749529B2 (en) * | 2005-02-08 | 2010-07-06 | Ash Access Technology, Inc. | Catheter lock solution comprising citrate and a paraben |
WO2006086779A1 (en) * | 2005-02-11 | 2006-08-17 | Teva Pharmaceutical Industries Ltd. | Amorphous ziprasidone mesylate |
ITMI20050346A1 (it) | 2005-03-07 | 2006-09-08 | Dipharma Spa | Forma solida di ziprasidone cloridrato |
CA2500667C (en) * | 2005-03-11 | 2013-01-15 | Apotex Pharmachem Inc. | Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions |
EP1858892A1 (en) * | 2005-03-14 | 2007-11-28 | Teva Pharmaceutical Industries Ltd | Anhydrous ziprasidone mesylate and a process for its preparation |
CA2599391A1 (en) * | 2005-03-14 | 2006-09-21 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of ziprasidone mesylate |
KR20070119678A (ko) * | 2005-04-13 | 2007-12-20 | 화이자 프로덕츠 인코포레이티드 | 지속 방출되는 나노입자 조성물을 제공하기 위한주사가능한 저장소 제제 및 방법 |
US20080305161A1 (en) * | 2005-04-13 | 2008-12-11 | Pfizer Inc | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
AU2006239900A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Therapeutic combinations for the treatment or prevention of psychotic disorders |
AU2006250340C1 (en) | 2005-05-26 | 2014-06-12 | Sumitomo Pharma Co., Ltd. | Pharmaceutical composition |
CN101879140A (zh) * | 2005-06-20 | 2010-11-10 | 依兰药物国际有限公司 | 包含芳基-杂环化合物的毫微粒和控制释放组合物 |
MX2007016151A (es) * | 2005-06-20 | 2008-03-06 | Elan Pharma Int Ltd | Composiciones de liberacion controlada y en forma de nano-particulas que comprenden compuestos aril-heterociclicos. |
EP2135603B1 (en) | 2005-11-22 | 2013-01-02 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
PT1954241E (pt) * | 2005-11-28 | 2012-06-01 | Orexigen Therapeutics Inc | Formulação de zonisamida de libertação sustentada |
PL379569A1 (pl) * | 2006-04-28 | 2007-10-29 | Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna | Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
EP1889844A3 (en) * | 2006-08-02 | 2008-03-05 | Krka | Polymorphic forms of ziprasidone sulphates |
EP1892243A1 (en) * | 2006-08-02 | 2008-02-27 | KRKA, tovarna zdravil, d.d., Novo mesto | Polymorphic forms of ziprasidone sulphate salts |
KR20190042766A (ko) | 2006-11-09 | 2019-04-24 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
TW200829235A (en) | 2006-11-09 | 2008-07-16 | Orexigen Therapeutics Inc | Methods for administering weight loss medications |
US20080286373A1 (en) * | 2007-05-18 | 2008-11-20 | Palepu Nageswara R | Ziprasidone formulations |
EP2197446A4 (en) * | 2007-08-31 | 2012-01-25 | Reddys Lab Ltd Dr | PREPARATION OF HYDROCHLORIDE OF ZIPRASIDONE MONOHYDRATE |
US8410268B2 (en) * | 2008-03-11 | 2013-04-02 | Alkem Laboratories Limited | Process for the preparation of ziprasidone |
EP2303025A4 (en) | 2008-05-30 | 2012-07-04 | Orexigen Therapeutics Inc | METHOD FOR TREATING DIGITAL FAT SWITCHES |
DE102008045854A1 (de) | 2008-09-05 | 2010-03-11 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung |
EP2445343B1 (en) | 2009-06-25 | 2021-08-04 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
EP2340834A1 (en) | 2009-12-30 | 2011-07-06 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Enhanced Solubility of Ziprasidone |
MX344303B (es) | 2010-01-11 | 2016-12-13 | Orexigen Therapeutics Inc | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. |
IL309564A (en) | 2010-02-25 | 2024-02-01 | Pfizer | Preparations containing apixaban |
WO2011148253A2 (en) | 2010-05-25 | 2011-12-01 | Aurobindo Pharma Limited | Solid dosage forms of antipsychotics |
SI23610A (sl) | 2011-01-13 | 2012-07-31 | Diagen@d@o@o | Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji |
EP4104824A1 (en) | 2012-06-06 | 2022-12-21 | Nalpropion Pharmaceuticals LLC | Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk |
EP2919788A4 (en) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA |
US11273158B2 (en) | 2018-03-05 | 2022-03-15 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264446A (en) * | 1980-09-09 | 1993-11-23 | Bayer Aktiengesellschaft | Solid medicament formulations containing nifedipine, and processes for their preparation |
MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
DE4141268A1 (de) * | 1991-12-14 | 1993-06-17 | Merck Patent Gmbh | Pharmazeutische zubereitung |
US5312925A (en) * | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
US5338846A (en) * | 1992-08-26 | 1994-08-16 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt |
US5359068A (en) * | 1993-06-28 | 1994-10-25 | Pfizer Inc. | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one |
DE69726206T2 (de) * | 1996-02-13 | 2004-04-15 | Pfizer Inc. | Prodrogen von 5-(2-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-on |
PT901786E (pt) * | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
-
1999
- 1999-05-27 US US09/320,985 patent/US6150366A/en not_active Expired - Lifetime
- 1999-06-04 HN HN1999000089A patent/HN1999000089A/es unknown
- 1999-06-08 AT AT99304451T patent/ATE240732T1/de active
- 1999-06-08 SI SI9930316T patent/SI0965343T1/xx unknown
- 1999-06-08 DK DK99304451T patent/DK0965343T3/da active
- 1999-06-08 PT PT99304451T patent/PT965343E/pt unknown
- 1999-06-08 EP EP99304451A patent/EP0965343B1/en not_active Expired - Lifetime
- 1999-06-08 DE DE69908021T patent/DE69908021T2/de not_active Withdrawn - After Issue
- 1999-06-08 ES ES99304451T patent/ES2197581T3/es not_active Expired - Lifetime
- 1999-06-08 GT GT199900080A patent/GT199900080A/es unknown
- 1999-06-09 TW TW088109645A patent/TW590774B/zh not_active IP Right Cessation
- 1999-06-09 SK SK769-99A patent/SK286245B6/sk not_active IP Right Cessation
- 1999-06-09 AU AU33983/99A patent/AU753820B2/en not_active Ceased
- 1999-06-10 SG SG1999002794A patent/SG77243A1/en unknown
- 1999-06-10 AP APAP/P/1999/001579A patent/AP1216A/en active
- 1999-06-10 IL IL13042496A patent/IL130424A/xx not_active IP Right Cessation
- 1999-06-11 CA CA002274338A patent/CA2274338C/en not_active Expired - Lifetime
- 1999-06-11 AR ARP990102822A patent/AR015553A1/es active IP Right Grant
- 1999-06-11 IS IS5079A patent/IS2182B/is unknown
- 1999-06-11 MY MYPI99002412A patent/MY121397A/en unknown
- 1999-06-11 TR TR1999/01379A patent/TR199901379A2/xx unknown
- 1999-06-11 PE PE1999000523A patent/PE20000632A1/es not_active Application Discontinuation
- 1999-06-14 PL PL380276A patent/PL195606B1/pl not_active IP Right Cessation
- 1999-06-14 PL PL333737A patent/PL195209B1/pl not_active IP Right Cessation
- 1999-06-14 HU HU9901960A patent/HU226487B1/hu not_active IP Right Cessation
- 1999-06-14 PA PA19998475601A patent/PA8475601A1/es unknown
- 1999-06-14 NO NO19992892A patent/NO316713B1/no not_active IP Right Cessation
- 1999-06-14 CN CNB991111192A patent/CN1307994C/zh not_active Expired - Fee Related
- 1999-06-14 ID IDP990571D patent/ID23546A/id unknown
- 1999-06-14 KR KR1019990021977A patent/KR100338915B1/ko not_active IP Right Cessation
- 1999-06-14 BG BG103489A patent/BG64691B1/bg unknown
- 1999-06-14 MA MA25621A patent/MA26647A1/fr unknown
- 1999-06-14 JP JP16677399A patent/JP3441676B2/ja not_active Expired - Lifetime
- 1999-06-14 CZ CZ0212799A patent/CZ297954B6/cs not_active IP Right Cessation
- 1999-06-14 RS YUP-271/99A patent/RS49611B/sr unknown
- 1999-06-14 OA OA9900126A patent/OA11064A/en unknown
- 1999-06-14 UA UA99063279A patent/UA59383C2/uk unknown
- 1999-06-14 HR HR990193A patent/HRP990193B1/xx not_active IP Right Cessation
- 1999-06-14 ZA ZA9903938A patent/ZA993938B/xx unknown
- 1999-06-14 NZ NZ336271A patent/NZ336271A/xx not_active IP Right Cessation
- 1999-06-15 CO CO99037319A patent/CO5070579A1/es unknown
- 1999-06-15 BR BR9902268-0A patent/BR9902268A/pt not_active Application Discontinuation
- 1999-06-15 EA EA199900467A patent/EA002223B1/ru not_active IP Right Cessation
- 1999-08-10 UY UY25649A patent/UY25649A1/es unknown
-
2000
- 2000-06-16 HK HK00103630A patent/HK1024184A1/xx not_active IP Right Cessation
-
2001
- 2001-06-11 JP JP2001175276A patent/JP4187423B2/ja not_active Expired - Lifetime
-
2003
- 2003-11-20 CY CY200300002C patent/CY2003002I1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR015553A1 (es) | Composiciones de ziprasidona, y procedimiento para prepararlas | |
BRPI0415437A (pt) | composto, processo para a preparação e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto | |
CO5560559A2 (es) | Formulacion de suspension oral estabilizada | |
AR009127A1 (es) | Procedimiento de preparacion de nanoparticulas de metilideno malona, particulas que contienen eventualmente una o mas moleculas biologicamente activas y composiciones farmaceuticas que las contienen | |
NO20040070L (no) | Mikroelektroniske rensesammensetninger inneholdende ammoniakkfrie flurodsalter | |
CA2597069A1 (en) | Pyridazine derivatives and their use as therapeutic agents | |
SG135204A1 (en) | Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation | |
AR033613A1 (es) | Un sachet hidrosoluble que comprende una composicion lavavajillas, un envase que comprende a dicho sachet hidrosoluble y un metodo para minimizar la formacion de manchas y pelicula que incluye a dicho sachet hidrosoluble | |
ECSP056023A (es) | Métodos para aislar la forma cristalina I de la 5-azacitidina | |
NO20023932D0 (no) | Nye forbindelser | |
DE60305724D1 (de) | Tetrahydrochinolin-derivate als crth2 antagonisten | |
CA2648234A1 (en) | Rheology enhancers | |
ATE317689T1 (de) | Schnelllösliche tabletten | |
TW200720258A (en) | Compound having triazole ring structure substituted with pyridyl group and organic electroluminescent device | |
CA2492718A1 (en) | Prodrugs of proton pump inhibitors | |
BR0207872A (pt) | Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração | |
NO20034667L (no) | Arylsulfonamider som antivirale midler | |
ATE175188T1 (de) | Polyaminderivate als strahlenschutzmittel | |
ATE332120T1 (de) | Shampoo mit hohlen teilchen | |
WO2008111389A1 (ja) | エッチング液及びエッチング方法 | |
SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
AR037098A1 (es) | Proceso para preparar un compuesto intermediario derivado de halo alquil sulfona y compuestos intermediarios que se usan en dicho proceso | |
AR044175A1 (es) | Compuestos de cefemo | |
DE60210339D1 (de) | Freifliessendes melamincyanuratagglomerat | |
SE9902742D0 (sv) | New pharmaceutical formultion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |